Treatment of Benign Prostatic Hyperplasia
Introduction to BPH Treatment
- The American Urological Association guidelines explicitly recommend combination therapy with an alpha-blocker and 5-alpha-reductase inhibitor (5-ARI) for men with moderate-to-severe Lower Urinary Tract Symptoms (LUTS) and enlarged prostates 1, 2
- The European Association of Urology guidelines strongly recommend offering combination treatment with an alpha-blocker and 5-ARI to men with moderate-to-severe LUTS and increased risk of disease progression (prostate volume >40 ml) 3
Rationale for Combination Therapy
- The combination of dutasteride and tamsulosin reduces clinical progression risk by 66% versus placebo, 34% versus finasteride alone, and 39% versus doxazosin alone 3
- The combination of dutasteride and tamsulosin reduces the relative risk of acute urinary retention (AUR) by 68% and BPH-related surgery by 71% compared with tamsulosin monotherapy at 4 years 3
- Alpha-blockers like tamsulosin provide rapid symptom relief (within 4 weeks) by relaxing prostatic smooth muscle 1, 2
- 5-ARIs like dutasteride reduce prostate volume over 3-6 months, preventing disease progression and reducing long-term complications 1, 4
Patient Selection and Monitoring
- Prescribe tamsulosin + dutasteride combination when prostate volume >30 cc on imaging, OR PSA >1.5 ng/mL, OR palpable prostate enlargement on Digital Rectal Examination (DRE) 6
- Moderate-to-severe LUTS (symptom scores indicating significant bother) is an indication for combination therapy 1, 6
- First follow-up at 4 weeks to assess alpha-blocker response and adverse effects 6
- Establish new PSA baseline at 3 months (dutasteride reduces PSA by approximately 50%) 6
Important Safety Considerations
- Both dutasteride and tamsulosin can cause sexual side effects including decreased libido, ejaculatory dysfunction, and erectile dysfunction 1, 7
- Tamsulosin has a lower probability of orthostatic hypotension compared to non-selective alpha-blockers like doxazosin 1, 4
- Patients with planned cataract surgery should be informed of Intraoperative Floppy Iris Syndrome (IFIS) risk and discuss with their ophthalmologist 6
Common Pitfalls to Avoid
- Do NOT use 5-ARIs in men without prostatic enlargement - they are ineffective in this population 1, 2, 4
- Do NOT expect immediate results from dutasteride - counsel patients about the slow onset of action (3-6 months) 3
- Do NOT use combination therapy for short-term treatment - benefits require long-term use (years), and combination therapy has higher adverse event rates 3
- Do NOT use mirabegron as primary BPH therapy - it is indicated for storage symptoms, not obstructive BPH 5, 3